Description of the largest cluster of tuberculosis notified in Norway 1997-2011: Is the Norwegian tuberculosis control programme serving its purpose for high risk groups?

BMC Public Health

Volumn 15, Issue 1, 2015, Pages

  Guzman Herrador, Bernardo R ^a,b   Rønning, Karin ^a   Borgen, Katrine ^a   Mannsåker, Turid ^a   Dahle, Ulf R ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

Cluster; Control programme; Elimination; Tuberculosis

Indexed keywords

ADOLESCENT; ADULT; AGED; CHILD; ETHNOLOGY; FEMALE; HUMAN; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MIGRANT; NORWAY; REFUGEE; RISK FACTOR; SENTINEL SURVEILLANCE; SOMALIA; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; EMIGRANTS AND IMMIGRANTS; FEMALE; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NORWAY; REFUGEES; RISK FACTORS; SENTINEL SURVEILLANCE; SOMALIA; TUBERCULOSIS; YOUNG ADULT;

EID: 84928042588     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-015-1701-x     Document Type: Review

References (22)

1. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2014. Stockholm: European Centre for Disease Prevention and Control; 2014.
2. Arnesen TM, Eide KÅ, Norheim G, Mengshoel AT, Sandbu S, Winje B. Tuberkulose I Norge 2013. (Tuberculosis in Norway 2013. Yearly report). Oslo: Norwegian Institute of Public Health; 2014. In Norwegian.
3. Winje B, Heldal E, Pettersen FO. Tuberculosis trends in Norway, 2002. Euro Surveill. 2003;7(42). http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2309
4. Dahle UR, Eldholm V, Winje BA, Mannsaker T, Heldal E. Impact of immigration on the molecular epidemiology of Mycobacterium tuberculosis in a low-incidence country. Am J Respir Crit Care Med. 2007;176(9):930-5.
5. forskrift om tuberkuloseontroll. Helse-og omsorgdepartementet; 2009. http://lovdata.no/dokument/SF/forskrift/2009-02-13-205.
6. WHO Sixty-Seventh World Health Assembly. Global strategy and targets for tuberculosis prevention, care and control after 2015. A67/11. Geneva: World Health Organization; 2014.
7. Diel R, Loddenkemper R, Zellweger JP, Sotgiu G, D'Ambrosio L, Centis R, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J. 2013;42(3):785-801.
8. Story A, van Hest R, Hayward A. Tuberculosis and social exclusion. BMJ. 2006;333(7558):57-8.
9. Forebygging og kontroll av tuberkulose: en veileder. Norwegian Institute of Public Health (In Norwegian); 2002. Available at http://www.fhi.no/dav/133D190B5E5C4E8393780C07DEE4CF7F.pdf.
10. Countries with high occurrence of tuberculosis (Land med høy forekomst av tuberkulose). Norwegian Institute of public Health (In Norwegian). Available at http://www.fhi.no/eway/default.aspx?pid=239&trg=List-6212&Main-6157=6263:0:25,6568&MainContent-6263=6464:0:25,6580&List-6212=6218:0:25,8229:1:0:0:::0:0.
11. Lov om vern mot smittsomme sykdommer [smittevernloven. (Norwegian Act relating to control of communicable diseases) available at http://lovdata.no/dokument/NL/lov/1994-08-05-55/KAPITTEL-7#§7-9.
12. Centers for Disease Control and Prevention. Tuberculin skin testing. http://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm.
13. Dahle UR, Sandven P, Heldal E, Caugant DA. Continued low rates of transmission of Mycobacterium tuberculosis in Norway. J Clin Microbiol. 2003;41(7):2968-73.
14. Millet JP, Shaw E, Orcau A, Casals M, Miro JM, Cayla JA. Barcelona Tuberculosis Recurrence Working G: Tuberculosis recurrence after completion treatment in a European city: reinfection or relapse? PLoS One. 2013;8(6):e64898.
15. Harstad I, Heldal E, Steinshamn SL, Garasen H, Winje BA, Jacobsen GW. Screening and treatment of latent tuberculosis in a cohort of asylum seekers in Norway. Scand J Public Health. 2010;38(3):275-82.
16. Harstad I, Jacobsen GW, Heldal E, Winje BA, Vahedi S, Helvik AS, et al. The role of entry screening in case finding of tuberculosis among asylum seekers in Norway. BMC Public Health. 2010;10:670.
17. Linas BP, Wong AY, Freedberg KA, Horsburgh Jr CR. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med. 2011;184(5):590-601.
18. Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, White PJ, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis. 2011;11(6):435-44.
19. Mandalakas AM, Menzies D. Is screening immigrants for latent tuberculosis cost-effective? Lancet Infect Dis. 2011;11(6):418-9.
20. Pareek M, Baussano I, Abubakar I, Dye C, Lalvani A. Evaluation of immigrant tuberculosis screening in industrialized countries. Emerg Infect Dis. 2012;18(9):1422-9.
21. Coker R. Compulsory screening of immigrants for tuberculosis and HIV. BMJ. 2004;328(7435):298-300.
22. Framework for tuberculosis elimination in low-incidence countries. World Health organization; 2014. Available at http://apps.who.int/iris/bitstream/10665/132231/1/9789241507707-eng.pdf.